

Siqing Fu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3321238/siqing-fu-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168
papers

6,329
citations

41
h-index

73
g-index

177
ext. papers

7,209
ext. citations

5.5
avg, IF

5.2
L-index

#	Paper	IF	Citations
168	Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101801	2.2	1
167	Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. <i>Cancer Medicine</i> , 2021 ,	4.8	4
166	A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. <i>Scientific Reports</i> , 2021 , 11, 22355	4.9	0
165	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. <i>British Journal of Cancer</i> , 2021 , 124, 1533-1539	8.7	6
164	Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , 2021 , 11, 5847	4.9	6
163	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021 , 5, 21	9.8	2
162	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021 , 26, 619-623	5.7	2
161	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021 , 26, 588-596	5.7	5
160	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021 , 4, 45-52	0.6	2
159	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021 , 19, 395-402	6.6	3
158	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 1247-1255	12.9	1
157	Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. <i>Investigational New Drugs</i> , 2021 , 1	4.3	0
156	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory 2020 , 8,		5
155	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1924-1931	12.9	26
154	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020 , 10, 3080	4.9	3
153	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 7	7.8	8
152	Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1204-1215	2.9	0

151	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019 , 21, e10348	7.6	9
150	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 145	22.4	17
149	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018 , 118, 763-769	8.7	16
148	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018 , 120, 137-141	5.9	22
147	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018 , 118, 1419-1424	8.7	4
146	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 181-188	12.9	89
145	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018 , 36, 416-423	4.3	13
144	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018 , 36, 601-607	4.3	58
143	Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 741-751	5.9	23
142	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33258-33270	3.3	4
141	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 671-676	6.1	23
140	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018 , 36, 638-646	4.3	102
139	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 877-885	3.5	4
138	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 407-418	3.5	37
137	Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2017 , 35, 59-67	4.3	4
136	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5648-5656	12.9	38
135	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	67
134	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017 , 2,	9.9	19

133	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017 , 23, 4155-4162	12.9	3
132	Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk Mutation. <i>Clinical Cancer Research</i> , 2017 , 23, 6541-6554	12.9	20
131	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017 , 7, 15963	4.9	17
130	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 616-626	4.3	19
129	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies 2017 , 5, 35		41
128	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017 , 92, 14-20	3.6	3
127	Outcomes of patients \geq 5 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017 , 140, 208-215	7.5	7
126	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 1388-1396	12.9	199
125	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials 2017 , 5, 100		67
124	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017 , 8, 33796-33806	3.3	3
123	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017 , 8, 87163-87173	3.3	
122	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2475-2485	6.1	49
121	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016 , 122, 3401-3409	6.4	40
120	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. <i>Cancer Discovery</i> , 2016 , 6, 1352-1365	24.4	150
119	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1397-404	6.1	61
118	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 575-81	3.5	5
117	Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 357-64	3.5	3
116	An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 15-30	5.9	7

115	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016 , 7, 67521-67531	3.3	36
114	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016 , 7, 23227-38	3.3	19
113	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016 , 7, 35132-43	3.3	9
112	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016 , 6, 35448	4.9	9
111	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016 , 5, 3437-3444	4.8	12
110	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016 , 76, 3690-701	10.1	154
109	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 1097-102	3.5	3
108	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 973-7	3.5	28
107	Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 728-38	3.8	27
106	Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. <i>Supportive Care in Cancer</i> , 2015 , 23, 2649-54	3.9	19
105	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Annals of Oncology</i> , 2015 , 26, 1012-1018	10.3	40
104	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 215-24	4.3	6
103	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015 , 33, 177-86	4.3	20
102	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. <i>Clinical Cancer Research</i> , 2015 , 21, 4801-10	12.9	48
101	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015 , 33, 700-9	4.3	11
100	Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 869-74	3.5	19
99	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015 , 33, 621-31	4.3	45
98	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. <i>Clinical Epigenetics</i> , 2015 , 7, 29	7.7	11

97	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. <i>Investigational New Drugs</i> , 2015 , 33, 911-20	4.3	7
96	MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e19-26	3.3	16
95	Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. <i>Gynecologic Oncology Research and Practice</i> , 2015 , 2, 10	4.5	9
94	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015 , 6, 12809-21	3.3	77
93	Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 1307-17	6.4	27
92	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015 , 15, 713	4.8	33
91	The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. <i>Oncologist</i> , 2015 , 20, 737-41	5.7	9
90	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11019-11019	2.2	5
89	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015 , 6, 20099-110	3.3	38
88	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. <i>Oncotarget</i> , 2015 , 6, 18693-706	3.3	19
87	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015 , 6, 28453-62	3.3	8
86	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015 , 6, 26886-94	3.3	38
85	Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 53, 563-72	2	7
84	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 495-501	3.5	39
83	Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. <i>Investigational New Drugs</i> , 2014 , 32, 154-9	4.3	7
82	Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. <i>Clinical Breast Cancer</i> , 2014 , 14, 468-74	3	25
81	Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. <i>Clinical Cancer Research</i> , 2014 , 20, 4827-36	12.9	150
80	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2014 , 32, 465-72	4.3	24

79	Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. <i>Investigational New Drugs</i> , 2014 , 32, 717-22	4.3	3
78	Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014 , 120, 2164-73	6.4	25
77	MABp1, a first-in-class true human antibody targeting interleukin-1 β in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. <i>Lancet Oncology, The</i> , 2014 , 15, 656-66	21.7	141
76	Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 194-203	7.3	3
75	Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3175-84	6.1	26
74	Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014 , 20, 6336-45	12.9	61
73	Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. <i>Clinical Cancer Research</i> , 2014 , 20, 5956-63	12.9	9
72	Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. <i>Oncologist</i> , 2014 , 19, 426-8	5.7	12
71	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. <i>Cell Reports</i> , 2014 , 6, 377-87	10.6	186
70	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014 , 32, 279-86	4.3	13
69	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. <i>Oncoscience</i> , 2014 , 1, 5-13	0.8	23
68	Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. <i>Oncoscience</i> , 2014 , 1, 540-9	0.8	20
67	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2014 , 5, 3029-38	3.3	36
66	MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. <i>Oncotarget</i> , 2014 , 5, 1837-45	3.3	24
65	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014 , 5, 1846-55	3.3	27
64	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. <i>Oncotarget</i> , 2014 , 5, 2349-54	3.3	50
63	Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014 , 5, 3871-9	3.3	10
62	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014 , 5, 8937-46	3.3	6

61	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014 , 5, 11168-79	3.3	47
60	Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. <i>Anticancer Research</i> , 2014 , 34, 2349-55	2.3	8
59	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 389-97	3.5	11
58	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. <i>Cancer Research</i> , 2013 , 73, 276-84	10.1	221
57	Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2013 , 31, 1192-200	4.3	39
56	Retreatment after secondary resistance or mixed response: a pilot study. <i>Oncology</i> , 2013 , 85, 350-5	3.6	1
55	Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. <i>Clinical Cancer Research</i> , 2013 , 19, 5474-84	12.9	58
54	Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. <i>Oncologist</i> , 2013 , 18, 1315-20	5.7	17
53	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2857-63	6.1	35
52	Reply to M. Rouanne et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 818	2.2	
51	Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2167-75	6.1	27
50	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. <i>Frontiers in Oncology</i> , 2013 , 3, 58	5.3	17
49	Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. <i>Oncotarget</i> , 2013 , 4, 884-93	3.3	18
48	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. <i>Oncotarget</i> , 2013 , 4, 772-84	3.3	15
47	Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. <i>Oncotarget</i> , 2013 , 4, 118-27	3.3	31
46	Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. <i>Oncotarget</i> , 2013 , 4, 156-65	3.3	29
45	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. <i>Oncotarget</i> , 2013 , 4, 705-14	3.3	87
44	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 126, 47-53	4.9	62

43	Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012 , 118, 1422-8	6.4	65
42	Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. <i>Clinical Cancer Research</i> , 2012 , 18, 5796-805	12.9	68
41	Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 297-303	3.8	6
40	Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. <i>Nutrition and Cancer</i> , 2012 , 64, 206-17	2.8	27
39	Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 2625-31	12.9	168
38	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 777-82	2.2	355
37	Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. <i>Cancer</i> , 2012 , 118, 6144-51	6.4	35
36	Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. <i>Clinical Cancer Research</i> , 2012 , 18, 2922-9	12.9	62
35	Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1034-41	4.6	12
34	Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. <i>Cancer Research</i> , 2012 , 72, 4616-21	10.1	60
33	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. <i>Clinical Cancer Research</i> , 2012 , 18, 6373-83	12.9	391
32	Mechanistic basis for overcoming platinum resistance using copper chelating agents. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2483-94	6.1	61
31	Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2891-6	2.2	22
30	Overcoming platinum resistance through the use of a copper-lowering agent. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1221-5	6.1	56
29	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. <i>PLoS ONE</i> , 2012 , 7, e38033	3.7	38
28	PIK3CA mutations in advanced cancers: characteristics and outcomes. <i>Oncotarget</i> , 2012 , 3, 1566-75	3.3	71
27	Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. <i>Hepato-Gastroenterology</i> , 2012 , 59, 960-4		1
26	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. <i>PLoS ONE</i> , 2011 , 6, e22769	3.7	153

25	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 558-65	6.1	281
24	Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 247-53	3.5	18
23	Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. <i>Cancer</i> , 2011 , 117, 1661-9	6.4	128
22	Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. <i>Cancer</i> , 2011 , 117, 5142-50	6.4	44
21	Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1300-7	6.1	19
20	Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3547-52	2.2	25
19	Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. <i>Oncologist</i> , 2011 , 16, 1292-8	5.7	53
18	Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. <i>Clinical Cancer Research</i> , 2010 , 16, 4031-7	12.9	15
17	Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. <i>Clinical Colorectal Cancer</i> , 2010 , 9, 311-4	3.8	8
16	Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1087-93	3.5	16
15	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010 , 116, 4086-94	6.4	22
14	Development of curcumin as an epigenetic agent. <i>Cancer</i> , 2010 , 116, 4670-6	6.4	129
13	Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 201, 367.e1-6	6.4	8
12	The changing face of phase 1 cancer clinical trials: new challenges in study requirements. <i>Cancer</i> , 2009 , 115, 1592-7	6.4	17
11	Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 200, 177.e1-9	6.4	45
10	Abstract B134: PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials 2009 ,		2
9	Update on aurora kinase inhibitors in gynecologic malignancies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008 , 3, 162-77	2.6	4
8	Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. <i>Pharmaceutical Research</i> , 2008 , 25, 2272-82	4.5	6

7	Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. <i>Gynecologic Oncology</i> , 2007 , 106, 375-80	4.9	8
6	Targeting Aurora kinases in ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 77-85	6.4	18
5	Proteomics in Gynecologic Malignancies. <i>American Journal of Cancer</i> , 2006 , 5, 299-317		
4	Clinical application of oxaliplatin in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 1717-32	3.5	24
3	Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). <i>Human Gene Therapy</i> , 1993 , 4, 821-34	4.8	9
2	Genetic therapy of human neoplastic disease. <i>Stem Cells and Development</i> , 1993 , 2, 373-5		
1	Molecular approaches to the diagnosis and treatment of cancer. <i>Stem Cells</i> , 1993 , 11 Suppl 3, 129-30	5.8	1